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Peripheral blood large granular lymphocytes (LGL)' are known as cells able to
spontaneously lyse certain tumor target cells through a non-MHC-restricted type
of recognition (NK activity) (1-5). LGL are phenotypically distinguishable from
T orBlymphocytes since theylack CD3/TCR complex or surface Ig(6, 7). Inaddi-
tion, they express cell surface markers such as CD16 and CD56 (NKH1, Leu-19)
(8-10). The range of tumor cell recognition, as well as the intensity of killing, was
shown to highly increase after culture ofNK cells in IL-2-containing media (lym-
phokine-activated killer activity) (11-14). Recently, we also provided evidence that
(at least some) CD3- cells mediate specific lysis of allogeneic cells after activation
in mixed lymphocyte culture (15, 16).
Triggering of the lytic machinery in CD3-CD16' lymphocytes is mediated not
only by interaction with tumor target cells but also by mitogens such as PHA (17).
As recently shown, a similar effect can be induced by appropriate mAbs directed
to cell surface molecules, including CD2 and CD16 (FcyR type III) (18-20). The
study of surface molecules able to mediate CD3-CD16' lymphocyte activation
(leading to signal transduction and triggering of thelytic machinery) may be impor-
tant to the definition of receptor structures involved in tumor cell lysis (21, 22). In
the present study, by the use of the GL183 mAb, we identified a novel 58 (55)-kD
surface molecule that is expressed on a subset of resting or activated CD16' and
CD56+ cells. The GL183 mAb allows the unambiguous identification oftwo pheno-
typically distinct NK subsets, thus providingclearevidence forhuman NK cell het-
erogeneity. Moreover, interaction of CD3-CD16' cells with the GL183 mAb results
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in NK cell activation characterized by [Ca2+ ]i increments and induction of the cell's
functional programs. Finally, the molecule defined by GL183 mAb appears to play
a role in the regulation of the NK cell activation induced via CD2 or CD16 surface
molecules.
Materials and Methods
Isolation and Culture of CD3-CD16'CD56' Lymphocytes.
￿
PBL from normal volunteers were
isolated by Ficoll-Hypaque gradients and subsequently separated into different subsets by
cell sorting and/or treatment with mAbs followed by complement depletion (15). To obtain
purified GL183' cells from PBL, cells were stained with GL183 mAb followed by an isotype-
specific (anti-IgGI) rabbit anti-mouse fluoresceinated antiserum (Southern Biotechnology
Associates, Inc., Birmingham, AL) as a second reagent. Purified CD16' cells were sorted
using the KDl anti-CD16 mAb (19) and a fluoresceinated anti-IgG2a second reagent. The
CD3-GL183- cell subset was obtained by treatment of PBL with anti-CD3 (OKT3) and anti-
CD4 (CK79) mAbs followed by complement depletion. The resulting CD3 -CD4- popula-
tion was then stained with GL183 mAb as described above, and GL183 - cells were isolated
by sterile sorting as previously described (23). Cloning of the various cell subsets was per-
formed under limiting dilution conditions in the presence of irradiated feeder cells and a
source of exogenous IL-2 (rIL-2; Cetus Corp., Emeryville, CA) as previously described for
both T and NK cells (15, 24). Clones were maintained in culture for periods of time varying
from 1 to 6 mo in the presence of 100 U/ml of rIL-2 at a cell concentration of -106/ml in
96 round-bottomed microwells (Greiner Labor Technik, Nurtinger, FRG).
Productionof GL183 mAb.
￿
5-wk-old male BALB/c mice were immunized with a cell clone
termed E57 (surface phenotype: CD3-CD16'CD56') as previously described (25). The im-
munization schedule consisted of 2 wk of intravenous injections of 107 E57 cells. After eight
injections, the mice were splenectomized and immune splenocytes were fused with P3U1
myeloma cells (25). The screening of hybridoma supernatants was based on the ability to
modulate the cytolytic function of E57 against the human ovarian carcinoma cell line termed
IGROV, used as "Cr-labeled target cells in a 4-h "Cr release assay. To this end, 1 .5 x 104
E57 cells were cultured together with 5 x 103 IGROV target cells (for a final E/T ratio of
3:1) in the presence of 50 ul of culture supernatants derived from the various hybridomas.
The assay was performed in V-bottomed microtiter trays in a final volume of 200 Al. After
4 h, 100 Al of supernatant was removed from each well and counted in a gamma counter
for the assessment of 5'Cr release. Percent specific release was determined as previously de-
scribed (23, 24). According to this screening procedure, a hybridoma, termed GL183, that
was able to increase the cytolytic activity of E57 clone against IGROV target cells, was iso-
lated and further subcloned in limiting dilution.
Two-color Flow Cytofluorometric Analysis.
￿
Analysis ofPBL for the distribution of the surface
antigen recognized by the GL183 mAb (GL183 antigen), as compared with that ofCD3, CD4,
CD8, CD16, CD56, and CD2 antigens, was performed using two-color fluorescence cytofluoro-
metric analysis, as previously described (9, 17). Cells were stained with GL183 mAb followed
by FITC-conjugated (or PE-conjugated) goat anti-mouse IgGI antibodies (Southern Biotech-
nology Associates, Inc.) and one of the following reagents: OKT3-PE (IgG2a), Leu-11-FITC
(IgM), OKT8-PE (IgG2a), OKT4-PE (IgG2a), Leu-5-FITC (IgG2a), and NKHI (IgM),
followed by appropriate anti-IgM PE antibodies. In some experiments, FITC-conjugated
GL183 mAb was used for double fluorescence analysis. OKT3, OKT8, and OKT4 mAbs
were purchased from Ortho Pharmaceutical, Raritan, NJ, whereas Leu-11, Leu-5, and Leu-
19 were purchased from Becton Dickinson & Co., Basel, Switzerland. The NKH1 mAb was
kindly provided by Dr. Thiery Hercend, Institut Gustave Roussy, Villejuif, France. Other
antibodies used for these analysis were MAR21 (anti-CD7) and MAR199 (anti-HLA-DR).
Characterization ofthe GL183 Molecule.
￿
Cloned GL183' cells were washed five times in cold
RPMI 1640, twice in PBS, and their surface was labeled with
1251 using the lactoperoxi-
dase/glucose oxidase catalyzed iodination (26). After labeling, cells were washed once with
PBS and resuspended (in ice) for 30 min in lysis buffer containing 1% NP-40. After spinning,MORETTA ET AL.
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the supernatants were filtered and dialyzed with PBS and precleared three times with 20
pl of packed protein A-Sepharose beads for 2 h under rotation. Lysates were then incubated
for 2 h with 200 Al ofGL183 culture supernatant. 201A of packed protein A-Sepharose beads
was then added, and samples were incubated overnight at 4°C under rotation. The immuno-
precipitate was eluted from protein A-Sepharose by boiling for 5 min in buffer containing
1% SDS in the presence or absence of 5% 2-ME and analyzed on 11 or 8% discontinuous
SDS-polyacrylamide gels (27). The nonequilibrium pH gradient electrophoresis (NEPHGE)
was carried out using pH 3.5-10 ampholines, followed by 11 % SDS-PAGE gels for size sepa-
ration, as described (28). The iodinated sample was applied at the acidic end.
FunctionalAnalysis ofCD3-CD16' Clones.
￿
The cytolytic activity of the various clones was
tested in a 4-h "Cr-release assay, as described above. In all instances, target cells were used
at a concentration of 5 x 104/ml and were represented by either human or murine tumor
cell lines, as described in Results. The E/T ratios ranged from 10:1 to 0.5:1, as indicated.
After titration, DEAE-Sephacel-purified GL183 mAb was used in most experiments at acon-
centration of 0.2 ng/ml resuspended in 50 pl of medium. The other mAbs, including VD4
(anti-CD16), KDl (anti-CD16), JT3A (anti-CD3), MAR206 (anti-C132), and CK90 (anti-
LFAl), were used at doses ranging from 2 to 0.2 ng/ml, depending upon preliminary titration
experiments. In most cytolytic experiments, GL183 mAb and/or the above-mentioned mAbs
were added at the onset of the culture together with effector and target cells. In other experi-
ments, GL183 mAb was added at different intervals during the cytolytic test, as indicated
in the figure. In this case, the other mAbs were added at the onset of the cytolytic test. The
determination ofTNF-a release by cloned cells was performed on cell-free supernatants ob-
tained from clones stimulated for 24 h by either PMA alone (0.5 ng/ml) or in combination
with either PHA (0.025% [vol/vol] of the stock solution), KD1 (anti-CD16), or GL183 mAb
(1 ng/ml).
The enzyme immunoassay used for the quantitative determination of TNFa was pur-
chased from T Cell Sciences, Inc., Cambridge, MA. The sensitivity of the test ranged from
10 to 1,200 pg/ml.
Determination of Free Cytoplasmic Cat' Concentration.
￿
Measurements of [Ca2+]; were per-
formed as previously described (17). Briefly, GL183' cloned cells were loaded with acetox-
imethyl ester of Fura-2 (1 p,M final concentration), and the fluorescence of the cellular sus-
pension (106/ml) was monitored with a spectrofluorimeter (LS-5; Perkin-Elmer Corp.,
Pomona, CA) using a 2-ml quartz cuvette. The cell suspension was excited at 340-380 nm
and fluorescence measured at 510 nm. 5-nm slit widths were used for both excitation and
emission. All measurements were performed at 37°C using a thermostatically controlled cuvette
holder and stirring apparatus. [Ca2+]; were calculated by the method of Grynkiewicz et al.
(29). In the Cat' depletion experiments, EGTA (final concentration, 10 mM) was added to
the cellular suspension from a 500-mM stock (pH 7.4) 1-10 min before the addition of the
stimulatory mAb.
Preparation ofF(ab')2 Fragments ofGL183 mAb.
￿
2 ml of DEAE-Sephacel (Pharmacia LKB
Biotechnology, Uppsala, Sweden) -purified IgG1 GL183 mAb (1 mg/ml) was dialyzed over-
night against acetate buffer (0.1 M, pH 3.8). Next, the mAb was digested with 50 pg ofpepsin
(Worthingthon Biochemical Corp., Freehold, NJ) for 6 h at 37'C, after which the digestion
was stopped with 3 M Tris-HCl, pH 8.6, and by placing the reaction mixture on ice. This
mixture was dialyzed overnight against 50 mM Tris-HCI, pH 8, and applied to a 10-ml DEAE-
Sephacel column. 1-ml fractions were collected and assayed spectrophotometrically at 280
nm and by 7 and 11% SDS-PAGE under reducing and nonreducing conditions, respectively.
Results
A lymphocyte clone termed E57 (surface phenotype CD3- , CD2+, CD7',
CD16+ , CD56+) derived from peripheral blood CD3- lymphocytes was used for
mice immunization. Clone E57, like most CD3 - lymphocyte clones, displayed cyto-
lytic activity against NK-sensitive (K562) and NK-resistant (IGROV P815, Raji,
M12, P3U1) target cells. The hybridoma supernatants were screened for their ability698
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to modulate the cytolyticactivity ofclone E57 againstthe human ovarian carcinoma
target cells termed IGROV. A mAb (termed GL183) that displayed the ability to
enhance the cytolytic activity of the immunizing clone was selected .
Distribution ofGL183 Antigen .
￿
Immunofluorescence analysis on PBL revealed that
cells reactive with GL183mAbranged between 2 and 12% (mean6.5%) in 10 different
donors analyzed .
To comparatively analyzethe expression ofGL183 antigen with that ofotherlym-
phocyte surface markers, further double fluorescence analysis was performed (Fig .
1) . When PBL were stained simultaneously withGL183 and anti-CD56mAbs (Fig .
1 B), all GL183' cells were also reactive with anti-CD56 (NKHI) mAb. However,
only a fraction of theCD56+ cell population reacted with GL183 mAb; in a series
of five experiments, the percent of CD56 + cells reactive with GL183 mAb ranged
between 20 and 55%. Similar figures were obtained with anti-CD16 mAbs . Thus,
FIGURE 1 . Distribution of
GL183' cells in PBL . PBL
were stained with PE-OKT3
(anti-CD3) and FITC-GL183
(A) or with PE-anti-CD56 and
FITC-GL183 (B). (C and D)
Cells were stained with PE-
GL183 and FITC-Leu-5 (anti-
CD2) or FITC-Leu-11 (anti-
CD16), respectively . (E and F)
Cells were stained with FITC-
GL183 and PE-OKT4 (anti-
CD4) or PE-Leu-2a (anti-
CD8), respectively . Thecontour
plotwas divided into quadrants
representing unstained cells
(lower left), cells with only red
fluorescence (upper left), cells
with red and green fluorescence
(upperright), and cells with only
green fluorescence (lowerright) .
Cells simultaneously stained in
redandgreen inA were <03%,
whereas in B, they represented
12.2% . In C, double fluorescent
cells were 5.1%, whereas cells
stained in red only (GL183',
CD2-) were 6.9% . In D,
double fluorescent cells were
12%, whereas cells stained in
green only (CD16', GL183-)
were 19%, and cells stained in
red only (GL183', CD16-)
were <0.3% . In E, double
fluorescent cells were <0.3%,
whereas in F, they were 3.6% .
This donor was selected for
double fluorescence analysis be-
cause of the high numbers of
CD16', CD56' (N30%) cells
present in peripheral blood .MORETTA ET AL.
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GL183+ cells were mostly confined into the CD16+ population (Fig. 1 D), however,
they represented only a fraction (ranging from 30 to 70% in four different individ-
uals) of these cells. On the other hand, >95% of GL183+ cells did not react with
anti-CD3 mAbs (Fig. 1 A). It should be stressed, however, that small proportions
were consistently CD3+. In addition, all GL183+ cells expressed CD7 antigen (not
shown), whereas they were heterogeneous with respect to CD2 antigen expression
(Fig. 1 C). In Fig. 1, E and F, the reactivity of GL183 mAb is compared with that
of anti-CD4 or anti-CD8 mAbs. While no GL183+ cells coexpressing CD4 antigen
could be detected (Fig. 1, E), a minor subset ofGL183+ cells consistently expressed
low amounts of CD8 antigen (CD8 dim; Fig. 1 F). Therefore, expression of GL183
surface antigen appears to define a subset of CD56+CD16+ cells. This concept was
further substantiated by the analysis ofdifferent CD3-CD16+CD56+ polyclonal cell
linescultured in IL-2. Consistently, only a proportion ofthesecell populations reacted
with GL183 mAb. GL183 mAb did not react with normal or EBVtransformed B
lymphocytes, restingor activated monocytes, and granulocytes. In addition, all the
tumor cell lines of T, B, or monocytic origin analyzed were GL183-. We can thus
conclude that GL183 antigen expression defines a subset of CD3-CD16+CD56+ cells
present in both fresh and cultured CD16+CD3- cell populations.
Isolation and Cloning of GL183+ Lymphocytes.
￿
Given the bimodal distribution of
GL183 antigen expression in PBL, GL183' cells could be easily separated by cell
sorting and cloned under limiting dilution conditions (23). In parallel experiments,
either CD16+ lymphocytes (purified by cell sorting) or CD3-GL183- lymphocytes
(obtained by treatment of PBL with anti-CD3 mAb and complement, followed by
FACS sorting of GL183- cells) were cloned for comparison under the same culture
conditions. Cloning efficiencies of CD16' or GL183+ cell populations were similar
in several experiments (and ranged between 1/3 and 1/10 cells). In addition, themajority
ofthe clones yielded cell numbers sufficient forsurfacephenotype analysis and func-
tional characterization. All the clones obtained from GL183`-sorted cells (>500
GL183+ clones have been analyzed) maintained the GL183+CD56+CD16+ surface
phenotype. The majority were CD3-CD2+4-8-; some clones, however, did not ex-
press detectable surface CD2 antigens (17). Clones expressing CD8 antigen repre-
sented -20% of all GL183' clones, while only one (F6.1) reacted with anti-CD4
mAb. It should be stressed that theintensity ofstaining with anti-CD8 or anti-CD4
mAbs in these CD3-GL183+ clones was rather weak in comparison with that of
CD3+/TCRce/a+ clones. Unfrequently, (N1%) GL183+ clones expressed surface
CD3 molecules. Among five different GL183+CD3+ clones analyzed so far, only one
expressed TCR--y/S, while the remaining were TCRodo*, as suggested by the lack
of reactivity with antiTCR-y/S mAb (30) and by the reactivity with WT31 mAb.
Interestingly, all these GL183+CD3+WT31+ clones were CD8+, and also expressed
antigens such as CD16, CD56, and CD11b, which are typical of NK cells (but infre-
quent in CD3+ cells). Phenotypic analysis of clones derived from purified CD16 +
lymphocytes revealed that approximately one in three expressed GL183 surface an-
tigens. In these experiments, the proportion of CD16+ clones expressing GL183 an-
tigen was similarto that of CD16+ cellsthat were GL183' in the starting PBLpopu-
lation. Finally, clones derived from CD3-GL183- lymphocytes expressed the
CD3-GL183-CD16+CD56+ surface phenotype, thus indicating that GL183 antigen
is not acquired in culture by GL183- precursors.700
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The analysis of the distribution ofGL183 antigen already suggested that it was
distinct from other known surface antigens expressed by CD3- cells ; still, the pos-
sibility existed that surface moleculescarrying GL183 determinantcouldbe associated,
in some CD3- cells, to other known surface molecules. To analyze this point, we
performed mAb-induced antigen capping experiments on GL183' clones . Thus, we
analyzed whethercappingofGL183 moleculesresulted in cocappingofNK cell-related
surface molecules recognized by anti-CD16, anti-CD56, NKH2, and Leu-7 mAbs .
Sincethe bindingof these mAbs was unaffected by cappingof the GL183 molecules,
we can conclude that the GL183 antigen is not physically associated to molecules
recognized by anti-CD16, anti-CD56, NKH2, or Leu-7 mAbs (not shown) .
Biochemical Characterization ofProteins Recognized by GL183mAb .
￿
We next analyzed
the biochemical characteristics ofthe surface antigen immunoprecipitated byGL183
mAb from a series of 1251 surface-labeled CD3-GL183' clones . Molecules immu-
noprecipitated by GL183 mAb were analyzed by SDS-PAGE under both reducing
and nonreducing conditions (Fig . 2). It can be seen that the material precipitated
by GL183 mAb in different clones was represented either by a 58-kD band or by
a broad 55-58-kD band . In some experiments, the 55-58-kD component revealed
the presence of two distincts bands . In 9 of 13 clones analyzed, surface molecules
precipitated by GL183 mAb were represented by the 55-58-kD proteins, whereas
four displayed the form with the 58-kD band only.
To better characterize themolecules reactive with theGL183mAb in the twodifferent
FIGURE 2 .
￿
SDS-PAGE analysis ofsurface moleculesimmunoprecip-
itated by GL183 mAbfrom CD56', CD16', GL183` clones. (A) Cells
(N5 x 10 6) from clones F6 .1 (lane a), CA9 (lane b), F25.58 (lane c),
and F25.12 (lane d) were surface labeled with 15 I using the lac-
toperoxidase technique, and lysed in buffer containing 1% NP-40.
Immunoprecipitationwasperformedby GL183 mAbcoupled to pro-
tein A-Sepharose beads . SDS-PAGE analysis was performed under
reducingconditions using 11% acrylamide gels . (B) Cells from clones
F6 .1 (lanes a and c) and F25.12 (lanes b and d) were treated as above
and finally run under reducing (lanes aand b) or nonreducing (lanes
c and d) conditions using 8% acrylamide gels .MORETTA ET AL.
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types of clones, we further performed two-dimensional PAGE analysis. As shown
in Fig. 3, the material precipitated by clone F6.1 (B) was characterized by a single
acidic spot corresponding to the 58-kD band observed in SDS-PAGE. On the con-
trary, GLI83 proteins immunoprecipitated by clone F25.58 (Fig. 3 A)were resolved
in two distinct spots showing slightly different PI. The apparent molecular mass
ofthese spots corresponded to the 55-58-kD bands detected in SDS-PAGE analysis.
More importantly, in two-dimensional PAGE, the spot withhigher molecular mass
(58 kD) immunoprecipitated from clone F25.58 migrated at the same isoelectric
point as the single spot immunoprecipitated from clone F.6.1. These data suggest
that the surface molecules immunoprecipitated by GLI83 mAb are composed of
a 58-kDmolecule that can be associated(as in clone F25.58) to an additional mole-
cule of 55 kD.
Antitumor Cytolytic Activity and TNF-a Production by GLI83+ and GL183-
Clones. Next, we analyzed whether GLI83+ clones differed from GLI83- ones with
respect to functional capabilities such as antitumor cytolytic activity and TNFa
production (31). To this end, a large number ofGLI83+ or GLI83- clones were ana-
lyzedfor theircytolyticactivity against twodifferentNK-resistant tumortarget cells
represented by the human ovarian carcinoma cell line IGROV and by the murine
mastocytoma P815. Fig. 4 shows the cytolytic activity of20 representative GLI83+
clones, as compared with that of 20 GLI83- clones tested at an E/T cell ratio of
1:1 . It is evident that, on average, GLI83+ clones lysed these tumortarget cellsless
efficiently than GLI83- ones. Although not shown, when analyzed at a higher E/T
ratio (i.e., 5:1), most GLI83+ clones efficiently lysed both types of target cells. In
most instances, approximately fivefold more effector cellswere required for GLI83+
clones in order to obtain the same cytolytic effect detected with GLI83- clones.
Next, the ability ofGLI83+ or GLI83- clones to produce TNFa after cell stim-
ulation was analyzed. Stimuliwere represented by PHA, or byanti-CD16 orGLI83
mAbs in the presence of0.517o ng/ml ofPMA. Cells (106 cloned cells/ml) were cul-
turedinthe variousculture conditions for 24 h, andculture supernatants were tested
for thepresence ofTNFa. As shown inTable 1, PHA or anti-CD16 (inthe presence
of PMA) induced release ofTNF by both GLI83+ and GLI83- clones. More im-
portantly, GLI83 mAb (inthe presenceofPMA) consistentlyinducedTNFproduc-
tion by GLI83+ clones. Neither PMA alone nor anti-CD16 or GLI83 mAb alone
induced significant TNF release in the clones analyzed.
Enhancement of Cytolytic Activity by GLI83 mAb.
￿
In preliminary experiments,
GLI83+ clones were shown tolyse (with different efficiency) a panel ofhumantumor
target cells, including U937 (myelomonocytic leukemia), Raji (Burkitt lymphoma),
IGROV(ovarian carcinoma), M14 (melanoma), and A549 (lungcarcinoma). Since
the GLI83 mAb had been selected on the basis ofits ability to modulate (i.e., in-
crease) the cytolytic activity of the GLI83+ clone E57 against IGROV target cells,
it was conceivable that a similar effect could be exerted also on the lysis of other
target cells. In Fig. 5, the cytolytic activity ofa representative GLI83+ clone (CA9),
either in the presence or in the absence ofthe mAb, is shown. It can be seen that
in the absence of GLI83 mAb, the various target cells displayed different degrees
ofsensitivity to lysis. More importantly, in all instances, addition of GLI83 mAb
resulted in a marked enhancement of the cytolytic effect. Thus, for example, M14
and A549 target cells at an E/T ratio of 3:1 were poorly lysed by CA9 cells alone,702
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however, >50% lysis was achieved at the same E/T ratio upon addition of GL183
mAb. Also, in the case of U937 target cells that were, per se, more susceptible to
lysis by CA9 effector cells, a marked increment of the cytolytic activity was detect-
able in the presence of the mAb (Fig. 5). Thus, in the presence of GL183 mAb,
the same degree of cytolysis could be achieved with 10-fold less effector cells. Since
none of the target cells expressed GL183 antigen, the mAb-induced enhancement
of cytolytic activity was not consequent to an antibody-dependent cellular cytotox-
icity mechanism, but it was likely to reflect the triggering of the effector cells by
the antibody. Similar results were obtained with all (>20) GL183+ clones analyzed
against the same panel of target cells.
Unlike other target cells, K562 were highly susceptible to cytolysis by the CA9
clone (and by all of the GL183+ clones analyzed). Addition of GL183 mAb did not
augment the cytolytic activity against these target cells, but rather, it had a minor
TABLE I
TNF Production by GL183* and GL183- Clones
FIGURE 4. Cytolytic activity
of GL183' and GL183- clones
against humanor murine NK-
resistant tumor target cells. 20
GL183' clones and20 GL183-
clones were assessed for cyto-
lytic activity at an E/T ratio of
1 :1 . 5lCr-labeled target cells
were represented by the human
ovarian carcinoma cell line
termed IGROV andby the mu-
rine mastocytoma cell line
termed P815. Percent specific
lysis was evaluated in a 4-h
"Cr assay.
2 x 105 cloned CD3-CD16' cells (either GL183* or GL183- ) were cultured in triplicate
microwells (final volume of 200 Al/well) for 24 h at 37°C in the presence of one or another
of the various stimuli. Supernatant fluids were collected and tested for TNF content using
an enzyme immunoassay as described.
' PMA was used at 0 .5 ng/ml in all instances. PHAwas used at afinal dilution of 1:400 of
the stock solution; anti-CD16 and GL183 mAbs were used at 1 ng/ml.
703
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"
Clone
GL183 antigen
expression None PMA'
Stimuli
PMA + PHA
Anti-CD16
+ PMA
GL183
+ PMA
Pg/ml
134T5 - 10 20 350 270 15
134T53 - 20 40 140 150 40
72F4 - 20 40 320 220 40
134T49 + 30 40 300 900 450
78F2 + 40 70 >1,200 >1,200 390
74F32 + <10 15 350 300 200704
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inhibitory effect. On theotherhand, it should be noted that, similar to GL183 mAb,
other stimuli, such as PHA or anti-CD16 mAb, were unable to enhance the lysis
of K562 cells mediated by CD3-CD16' clones (not shown).
GL183 mAb Inhibits the Cytolytic Activity of CD3-GL183+ Clones against Certain Mu-
rine Target Cells. The Fc-y receptor-positivemurine mastocytomaP815 has been ex-
tensively used in previous studies for mAb-dependent redirected killing assays using
either CD3+ or CD3- effector cells and mAbs capable of triggering their cytolytic
functions(19, 30). Therefore, this cytolyticassay wasused to analyzewhetherGL183
mAb could enhance the cytolytic activity ofGL183+ clones. The data obtained with
the clone CA9, representative of 16 CD3-GL183+ clones, are shown in Fig. 6. It
is evident that GL183+ cells were able to lyse (to some extent) P815 cells in the ab-
sence of added stimuli. Addition of GL183 mAb, in this case, resulted in a strong
P 815
￿
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￿
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FIGURE 5.
￿
Enhancement of cytolyticac-
tivity by GL183mAb. CloneCA9(surface
phenotype: CD16*, CD3-, CD56*,
GL183*, CD2*) was tested for cytolytic
activity at different E/T cells as indicated.
"Cr-labeled target cells were represented
by human NK-resistant cell linestermed
IGROV (ovarian carcinoma), Raji (Bur-
kitt lymphoma), A549 (lungcarcinoma),
M14(melanoma), U937 (myelomonocytic
leukemia), and by the NK-sensitive cell
line K562. GL183 mAb (5 ng/ml) was
added to the cytolytic test at the onset of
the 4-h "Cr release assay. Cytolytic ac-
tivity in thepresence (")or in theabsence
(O) of GL183 mAb.
FIGURE 6.
￿
Cytolytic activity of GL183'
clones against murine target cells is in-
hibited by GL183 mAb. The same clone
CA9 used in the experiments reported in
Fig. 5 was tested for cytolytic activity
against S'Cr-labeled target cells in a 4-h
"Crrelease assay. Target cells were rep-
resented by the murine mastocytoma cell
line termed P815, by the murine B lym-
phoma M12, andby themurine myeloma
P3U1. GL183 mAb(0.2 ng/ml) wasadded
at theonsetofthe cytolytic test. Cytolytic
activity in the presence (") or in the ab-
sence (O) of GL183 mAb.MORETTA ET AL.
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inhibition of cytolysis. An inhibitory activity of GL183 mAb on all (>50) GL183+
clones tested could also be detected in cytolytic assays in whichtarget cellswere rep-
resented by the murine B lymphoma M12 or the murine myeloma P3U1 (Fig. 6).
Thus, it appears that, in cytolytic assays against these murine target cells, GL183
mAb results in effects that are opposite those observed with humantarget cells. Per-
haps more importantly, the effect of GL183 mAb was antithetical to that previously
described for other stimuli, including PHA, anti-CD16 mAb, and anti-CD2 mAb
(18, 19). Thus, as shown in Table II, PHA, anti-CD16 mAb, and anti-CD2 mAb
strongly enhanced the cytolytic activity against P815 target cells mediated by
CD3-GL183* or CD3-GL183- clones. Note that, in agreement with previous data
from our and other laboratories (18, 19), single stimulatory anti-CD2 mAbs could
trigger the lytic machinery of CD3-CD16+ cells (Table II). It is evident that GL183
mAb had, instead, a marked inhibitory effect on all five representative GL183*
clones reported. On the other hand, GL183 mAb had no inhibitory effect on the
two CD3-GL183- clones used as control. Note also that the GL183+ clones reported
in Table II were representative of the various phenotypic groups described above
for the CD3-GL183* peripheral blood cells. Thus, the expression or lack of expres-
sion of surface antigens such as CD2, CD8, or CD4 does not appear to influence
the susceptibility to inhibition by GL183 mAb.
Inhibitory Effect of GL183 mAb on the Redirected Killing Induced by PHA, Anti-CD16,
or Anti-CD2 nzAbs. Since the effect of GL183 mAb on the cytolytic activity against
P815 target cells was opposite that induced by other stimuli (including PHA, anti-
CD2 mAb, andanti-CD16mAb), this cytolytic assaywasappliedto investigate whether
a functional relationship existed among different stimuli acting on CD3-GL183*
cells. To this end, GL183 mAbhasbeen addedto thecytolytic assay in combination
with one or anotherstimulus. Table IIIshows the cytolyticactivity of four represen-
TABLE II
Effect of mAbs on the Cytolytic Activity of CD3- CD16* CD56*
Clones against P815 Target Cells
' The first five clones were GL183*, whereas the two remaining clones were
GL183- . All the clones were CD3-CD16*CD56* . Clone F6.1 was CD4*,
clones F25.58 and F25 .52 were CD8*, whereas the remaining were
CD4- CD8- . All the clones expressed CD2 surface antigens, with the excep-
tion of F25.12 and F12.8 .
GL183* clones were tested at an E/T ratio of 5:1 . The two GL183- clones,
3M30.2 and 3M12 .5, were tested at an E/T ratio of 1 :1 in view oftheirhigher
"spontaneous" cytolytic activity against P815.
5 Results are expressed as percent 51Cr release.
Clone'
GL183
antigen
expression None
Stimuli
PHA
added to
Anti-
CD16
the
Anti-
CD2
cytolytic test
GL183
Anti-
LFA-1
F6.1t + 485 79 88 67 6 14
F25.58 + 54 85 100 71 11 19
F25.12 + 33 72 78 35 4 8
F12.8 + 29 64 73 29 5 7
F25.52 + 61 92 98 84 16 27
3M30.2 - 46 85 99 ND 48 12
3M12.5 - 57 88 100 80 55 15706
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TABLE III
GL183 mAbs Inhibit Spontaneous and Redirected Killing Induced
by PHA or Anti-CD16 and Anti-CD2 mAbs
The different stimuli and GL183 mAbs were added at the onset of the 4-h
S1Cr release assay. The anti-CD16 mAb was represented by the VD4 mAb
(IgGl), whereas the anti-CD2 mAb was the MAR206 mAb (IgGl).
Cloned cells were assessed for cytolytic activity against P815 target cells at
an E/T ratio of 5:1, with the exception of clone 3M12.5 (GL183- ), which
was used at an E/T ratio of 1 :1 .
Data are expressed as percent specific "Cr release. The numbers in paren-
theses indicate the values in the absence of GL183 mAb, whereas data out
of parentheses indicate the values of the presence of GL183 mAb.
tative GL183+ clones in the presence or absence of various stimuli. It is evident that
GL183 mAb inhibited the lysisof P815 cells not only in the absence ofadded stimuli
(referred to as "spontaneous"killing), but also when stimulatory mAbs or PHAwere
added to the cytolytic assay (referred to as "redirected" killing). Note also that, in
thepresence ofGL183 mAb, thelevels of target cell lysis in experimentsof redirected
killingwere lowerthan the spontaneous lysis(independent upon the stimulus used).
For example, clone F25.52 at an E/T ratio of 5:1 had a spontaneous lysis of 54%,
whereas in the presence of anti-CD16 mAb, lysis reached 98%. Addition of GL183
mAb at the onset ofthe cytolytic assayreduced the spontaneouskillingto 13 % (from
54%), and the redirected killing mediated by anti-CD16 mAb to 28% (from 98%).
Maximal inhibitory effect on the spontaneouskillingwas stillobserved with amounts
of purified GL183 mAb of 0.1 ng/ml, whereas >50% inhibition was detectable at
0.01 ng/ml (Fig. 7). Thus, maximal inhibition could be obtained with -100-fold
less mAb, as compared with the amount required for maximalstimulation (10 ng/ml).
We further analyzed the inhibitory effect achieved upon addition of GL183 mAb
at different time intervals during the cytolytic test. In this assay, clone F25.58 (sur-
face phenotype: GL183+CD3-CD16+CD56+CD2+CD8+) was tested for cytolytic ac-
tivity against P815 target cells either in the presence or in the absence of various
stimuli. As shown in Fig. 8, addition of GL183 mAb strongly inhibited cytolysis
in both spontaneous and redirected cytolyticassaywhen added during the firsthour
of the assay. Approximately 50% inhibition was still detectable within 2 h from the
onset of the assay. The inhibitory activity of GL183 mAb in antibody-induced
redirected killingcouldbe due, at leastin part, to competition for antibody binding
to FcyR expressed on P815 target cells. However, the mAb MAR 21 (anti-CD7)
of the same IgG1 isotype (which reactedwith the effector cell surface) hadno inhibi-
tory effect (not shown). Moreover, GL183 mAb (IgGI) could also inhibit the cyto-
lytic activity induced by an anti-CD16 stimulatory mAb of the IgG2A isotype (not
Stimuli added to the cytolytic test
CloneS
GL183 antigen
expression None PHA
Anti-
CD16 Anti-CD2
F25 .52 + 13 (54)S 26 (89) 28 (98) 15 (79)
F25 .58 + 6 (46) 11 (82) 21 (94) 10 (73)
F6.1 + 9 (41) 14 (75) 16 (92) 8 (71)
F12 .8 + 5 (23) 8 (68) 15 (72) 8 (23)
3M12.5 - 57 (60) 92 (91) 103 (100) 74 (86)w
loo
so
25
0
Time (min)
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shown). These dataindicate that inhibitionofmAb-induced cytolytic activity isnot
due to competition for the FcyR expressed by P815 cells.
Finally, inhibition ofcytolysis was not consequent to competitive binding ofthe
various mAbs to the surface antigens expressed on the effector cells. Indeed, anti-
CD16or anti-CD2 mAbs (IgG2a isotype) efficiently bound to effector cells precoated
with GL183 (IgGl), as assessedbyanti-mouse subclass-specificsecond reagent (data
not shown).
Effect ofF(ab')2Fragments ofthe GL183mAb on the CytolyticActivity Mediated by CD3-,
GL183+ NK Clones. Since GL183 mAb was able to modulate the cytolytic func-
tion ofGL183+ clones, resulting in either augmentation or inhibition ofthe cyto-
lytic activity, we analyzed whether both phenomena could also be induced by the
F(ab')2 fragment ofthe antibody. It has previously been shown that cloned NK cells
could be activated with the F(ab')2 fragments ofanti-CD2 mAbs (32). On the other
hand, the enhancing effects ofanti-CD16 mAbs were confined to mAbs ofIgG iso-
707
FIGURE 7.
￿
Enhancing or in-
hibitory effect ofGL183mAbor
its F(ab')2 fragments on the
cytolytic activity mediated by
GL183' cells against human or
murine tumorcells. ClonePE5
(surface phenotype: GL183',
CD3-, CD16', CD7', CD2')
was tested (at an E/T ratio of
3:1)for cytolyticactivityagainst
the human IGROV and the
murine P815 cell lines in the
presence of graded amounts of
purified GL183 mAb (A) or
GL183 F(ab')2 fragments (").
FIGURE 8.
￿
Time-course analysis of inhibition
of cytolytic activities mediated by GL183 mAb.
Clone F25.58 (surface phenotype: GL183',
CD3-, CD16', CD56', CD2', CD8') was
tested (at an E/T ratio of 3:1) for spontaneous
andredirected cytolytic activity either in theab-
senceor in thepresence ofGL183mAb. This an-
tibody (0.2 ng/ml) wasaddedtothecytolyticassay
either at the onset or afterdifferent intervals as
indicated. Controls included spontaneous killing
ofP815 cellsmediated by clone F25.58 (") and
redirected killing in the presence of anti-CD2
mAb (0) or anti-CD16 mAb (A). Redirected
killing inducedby anti-CD16mAbwas tested for
inhibition with GL183mAb(A), whichwasadded
at different intervals. Redirected killing induced
by anti-CD2 mAb tested for inhibition with
GL183 mAb (0). Spontaneous killing tested for
inhibition with GL183 mAb (O).708
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type (18, 19), reflecting the need to bind to the Fc-yR expressed on target cells. The
F(ab')2 fragments of GLI83 mAb maintained the same (enhancing) effects of the
whole antibody at all concentration tested (Fig. 7). On the contrary, no inhibitory
effect in the cytolytic assay using P815 could be observed, thus, suggesting that, in
this case, binding of mAb to surface Fc-yR is strictly required to mediate the func-
tional effect. The inhibitory effect of GLI83 mAb couldbe achieved even with min-
imal amounts ofantibody (Fig. 7). Therefore, as a wide range of antibody dilutions
have been tested, it is possible to conclude that GLI83 F(ab')2 retains the effect of
theentire antibody in enhancing, butnot in inhibiting, lysis ofappropriatetarget cells.
GLI83 mAb Induces Ca2+ Mobilization in GLI83+ Cells.
￿
As shown in previous
studies, triggering of CD3-CD16+ cell populations or clones with PHA (17), anti-
CD2 mAb (17, 33), or anti-CD16 mAb (34) results in [Ca211, increments. There-
fore, we investigated the role of free cytoplasmic Cat+ levels in the signal transduc-
tion after cell triggering with GLI83 mAb. As shown in Fig. 9, when clone PE5
(surface phenotype: GLI83*CD3-CD16+CD7+CD2+CD8 -) was stimulated with
GLI83 mAb, a rapid increase of [Ca2+]; levels followed by a plateau phase could
be observed. These [Ca21], increments were similar to those induced by PHA used
as positive control. Experiments of Ca2+ mobilization performed in the presence
of EGTA indicated that GLI83 mAb, similar to other stimuli such as PHA, anti-
CD2 mAb, or anti-CD16 mAb (17, 34), induces a rapid Cat' release from internal
stores followed by an influx from the extracellular compartments (not shown).
Discussion
In the present study, by the useof GLI83 mAb, we describe a novel surfacemole-
cule expressed by a subset of human CD3-CD16 + (NK) cells. More importantly,
the molecules defined by GLI83 mAb were shown to be involved in mechanisms
of CD3- lymphocyte activation. Finally, GLI83 molecules appear to exert aregula-
tory role in the control ofcell activation inducedby different stimuli, including anti-
CD16 mAb, anti-CD2 mAb, and PHA.
Analysis of GLI83 antigen distribution in resting PBL demonstrated that the
GLI83+ cell population was mostly confined to the CD3-sIg- cell fraction having
the morphological characteristics of LGL. In addition, double fluorescence analysis
showed that expression of GLI83 surface antigen characterized a subset of CD16+
or CD56+ cells. Since these markers are known to be expressed by essentially all
NK cells (8-10), GLI83 mAb appears to identify a subset of PB NK cells. It is
noteworthy that GLI83 antigen was also expressed on <1°Jo CD3+ cells. As shown
by the clonal analysis of this very minor subset, these cells were also characterized
4W
C 250
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FIGURE 9.
￿
GLI83 mAb induces in-
crements of [Ca21], in GLI83* clones.
Comparative analysis of [Ca2*]; in-
crease in thePE5clone(surface pheno-
type: GLI83+ CD3-, CD16*, CD7*
CD2+ CD8-) after stimulation with
GLI83 mAb (A) or PHA (B). The
stimuli were added in presence of 1
mM extracellular Ca2*. Arrows indi-
cate the time of the addition of the
stimuli.MORETTA ET AL.
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by the expression of CD56 and CD16 surface antigens. Thus, CD3+GL183+ cells
appear to belong to a previously defined minor subset of CTL characterizedby the
coexpression of NK cell markers (35).
That expression or lack ofexpression ofGL183 surfaceantigen represents astable
phenotypic characteristic of NK lymphocyteswas clearlydemonstrated by theclonal
analysis of purified PB-derived GL183+ or CD3-GL183- lymphocyte populations.
Indeed, all clones (>500) derived from GL183+ populations expressed GL183 sur-
face molecules. Moreover, in no instances had clones derived from CD3-GL183-
lymphocyte fractions acquired GL183 surface antigen during culture.
Since a certain degree of heterogeneity has been well documented among CD3-
NK cells, particularly with respect to cytolytic function (36), we investigated whether
CD3-GL183+ cells differed from CD3-GL183- cells in their ability to lyse tumor
target cells. Although not shown, freshly isolated peripheral blood CD3-GL183+
and CD3-GL183- cells displayed similar levels of cytolytic activity against the clas-
sical NK-sensitive target K562. Analysis of thetwo subsets at the clonal level showed
again similar cytolytic activities against K562 . However, when tested against NK-
resistant target cells, GL183- clones displayed a higher cytolytic activity than those
expressing GL183 surface antigen. On average, GL183+ cloned cells were approxi-
mately fivefold less effective than GL183- ones in lysis of NK-resistant tumor target
cells. These data support the conceptthat expression ofGL183 antigendiscriminates
between two distinct subsets of CD3- NK cells that, after clonal expansion, mediate
different levels of cytolytic activity against NK-resistant tumor cells.
Morphological analysis of GL183+CD16+ and GL183-CD16+ lymphocytes after
isolation from peripheral blood or after clonal expansion indicated that both cell
types display LGL morphology (data not shown).
GL183 mAb was selected on the basis of its ability to modulate thecytolytic func-
tion of CD3-CD16* lymphocytes clones. The ability of GL183 mAb to enhance
target cell lysis was not restricted to the ovarian carcinoma IGROV cells used in
the screening of hybridomasupernatants, butwas also detectable in a panel of human
target cells of different hystotype (Fig. 5). Again, an exception was provided by the
K562 erythroleukemia target cells. In fact, no enhancement of K562 lysis by
GL183+ clones could be observed either in the presence of GL183 mAb (rather there
was a small inhibition) or in thepresence ofotherstimulisuch as PHAor anti-CD16
mAb (not shown). The finding that GL183 mAb efficiently triggers GL183+ effector
cells to lyse a number of human tumor targets indicates that GL183 surface mole-
cules are able to mediate cell activation upon binding with specific mAbs. These
data arefurther substantiated by the analysis ofTNFaproduction and by the study
of Cat' mobilization in response to this mAb. Thus, production of TNF was in-
duced by GL183 mAb in the presence of PMA, and levels of [Ca
21], increase similar
to those observed in the presence of PHA could be obtained by addition of soluble
GL183 mAb. Also, CD2 and CD16 surface molecules have been shown to mediate
CD3-CD16+ cell activation characterized by Ca2+ mobilization and triggering of
the lytic machinery upon binding of specific mAbs (18-20). However, the distribu-
tion of CD2 andCD16 molecules is clearly different from thedistribution of GL183
antigen (which is restricted to asmallercell fraction). In addition, cocappingexperi-
ments designed to study whether GL183 determinants were associated to other sur-
face molecules clearly indicated that GL183 antigen is not physically associated to
CD16 or CD2 surface molecules.71 0
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While GL183 mAb enhanced the cytolytic activity of GL183' clones against
human tumorcells, an opposite effect was observed against murine target cells. Thus,
addition ofGL183 mAb sharply inhibited the spontaneouslysis of P815, P3UI, and
M12 murine target cells by GL183' clones. In addition, while the F(ab')2 fragments
of GL183 mAb could efficiently enhance the lysis of human target cells (whether
FcyR', as the U937 cell line, or FcyR-, as the IGROV ovarian carcinoma line),
they had no inhibitory effect on the cytolysis of the FcyR' murine target cells
(P815). These results suggest that different mechanisms may be involved in the pro-
cess of induction-inhibition ofcytolysis mediated by GL183 mAb. Forexample, the
different effect induced by GL183 mAb on the lysis of human or murine target cells
may reflect differences in the type and/or number of cell-cell interaction molecules
involved in the process of binding of effector cells to human or murine target cells.
Whatever the molecular basis of these phenomena could be, the inhibitory effect
induced by GL183 mAb on the lysis of murine target cells further supports the con-
cept that GL183 molecules are involved in mechanisms of CD3- NK cell activa-
tion. In addition, in the cytolytic assay against murine P815 cells, GL183 mAb had
an effect that was clearly opposite that of other stimuli, including PHA, anti-CD16
mAb, anti-CD2 mAb (19). These data allowed us to analyze the possible functional
interactions existing among different pathways of CD3- cell activation. We found
that GL183 mAbstrongly inhibited the target cell lysis also when added in combina-
tion with stimulatory mAbs (anti-CD2 or anti-CD16) or PHA. These data suggest
that GL183 molecules may exert a regulatory control on other pathways of CD3-
CD16' lymphocyte activation. Although the molecular mechanisms involved in this
regulatory control remain to be defined, thedownregulation induced by GL183 mAb
on other pathways of CD3- cell activation is reminiscent of that detectable in CD3'
cells after mAb-induced modulation of the CD3/TCR molecular complex (37).
Preliminary biochemical characterization of surface molecules immunoprecipi-
tated by GL183 mAb demonstrated that GL183' clones may express different forms
of GL183 mAb-reacting molecules. Thus, in SDS-PAGE, some clones displayed a
single 58-kD chain, whereas in the majority ofthe clones analyzed, a broad 55-58-
kD band could be observed. Two-dimensional PAGE analysis allowed us to identify,
within this broad band, two distinct chains displaying slightly different molecular
masses and PI. In addition, this type of analysis showed that the 58-kD chains of
different clones migrate to identical positions. It is clearly necessary to compara-
tively analyze the 55- and 58-kD chains in order to determine to what extent they
are related oneto another. In this context, deglycosilation ofisolated chains together
with peptide mappinganalysis should clarify whether, indeed, the twochains repre-
sent different molecular products. So far, no difference in the functional capability
(cytolytic activity or TNF production) or in the surface phenotype (i.e., expression
or lack ofexpression ofCD2, CD8, or CD4 antigens)has been detected amongclones
expressing oneor an anotherform of GL183-reactive molecules. In the murine system,
recent evidence has been provided fortheexistence ofat leasttwo distinct NK subsets
based on the reactivity with a mAb termed SW5E6 (38). Thus, SW5E6' cells rep-
resent -40-50% of murine peripheral NK cells and ti50% of IL-2-expanded NK
cells. In addition, the SW5E6 mAb was shown to immunoprecipitate a 54-kD mole-
cule from the surface of murine NK cells. These data are clearly compatible with
those obtained in the human system with the GL183 mAb, with the exception that,MORETTA ET AL.
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in the mouse, two 54-kD chains are usually bound together by disulphide bonds,
whereas the 55-kD molecule recognized by GL183 mAb is found associated to a
58-kD chain in the absence ofdetectabledisulphide bonds. It is possiblethat GL183
and SWE56recognize similartypesofmolecules, althoughthesubsetsthat are defined
maynotnecessarilydisplaythe same functionalcharacteristics (38). A surface mole-
cule involved in NK cell activation has been recently identified on rat LGLs. Inthis
case, however, neither the molecular mass northe cellular distribution ofthis mole-
cule was reminiscent of that recognized by GL183 mAb (39).
Taken together, our data suggest that GL183 surface molecules may exert a role
in the activation/regulation of the cytolytic function of human NK cells. In view
of the restricted subset distribution of GL183 molecules and oftheir involvement
inthe activation ofthis cellsubset, it ispossible thatGL183 molecules may represent
a receptor-like structure involved in the cytolytic function of these cells. One may
speculate thatGL183 could representamonomorphic"receptor" moleculeuniquely
expressedby thissubset. Alternatively, the antigenicdeterminant recognized by GL183
mAb may be part ofa polymorphic portion ofa still undefined molecule expressed
by all CD3- NK cells. Ifthis holds true, surface structures analogous to GL183 mol-
ecules should be expressed also by CD3-GL183- cells, and mAbs should be
identified that are capable of recognizing these molecules. Experiments aimed to
identify "functional" surface structures expressed by CD3-GL183- lymphocytes are
in progress in our laboratory.
Summary
The GL183 mAb was obtained by immunizing BALB/c mice with the E57 clone
(CD7'CD2+CD3 -CD16'CD56') derived from human peripheral blood NK cells.
In human peripheral blood, GL183-reactive cellsranged between 2 and 12% (mean
6.5%) in 10 different donors. Double fluorescence and FRCS analysis showed that
GL183' cells were consistently included in the CD56' or CD16' cell populations.
Moreover, since only a fraction of CD56+ or CD16' cells (-40%) coexpressed
GL183 surface antigen, reactivity with GL183 mAb appears to define two subsets
within the CD3- lymphocyte population expressing NK cell markers. Although,
the majority of GL183' cells were CD3-, tit% expressed CD3 surface antigens.
As shown by clonal analysis, these infrequent CD3'GL183' cells coexpressed CD56
and CD16 antigens. Cloning of CD3-GL183' or CD3-GL183- cell populations
under limiting dilution conditions yielded clonal progenies that maintained their
original surface phenotype. Therefore, expression or lack ofexpression of GL183
surface antigens represents a stable phenotypic property ofasubset ofhuman CD3-
NK cells. Immunoprecipitation experiments and two-dimensional PAGE analysis
indicated that GL183-reactive molecules were represented in different clones either
by a single 58-kD chain or, more frequently, by two chains of -55 and -58 kD,
respectively. Analysis of GL183 " or GL183- NK clones for their ability to lyse
human (IGROV I) or murine (P815) tumor target cells indicated that GL183-
clones were, on average, fivefold more efficient in inducingtarget cell lysis. GL183'
and GL183- clones produced comparable levels ofTNFa in response to PHA plus
PMA or anti-CD16 mAb plus PMA. Importantly, production of TNFa was also
induced by stimulation ofGL183' clones with GL183 mAb plus PMA. These data
indicated thatGL183 antigencouldmediatecelltriggering. Thisconcept wasconfirmed71 2
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by the analysis of Ca2+ mobilization, as GL183 mAb induced (in GL183+ clones)
increments of [Ca2+]; comparable with those induced by PHA. Moreover, GL183
mAb, or its F(ab')2 fragments, strongly enhanced the cytolytic activity of GL183+
clones against a panel of human tumor target cells, including U937, Raji, IGROV
I, M14, and A549. In contrast, GL183 mAb, but not the F(ab')2 fragments, sharply
inhibited the cytolytic activity of the same clones against P815, M12, and P3U1 mu-
rine target cells. In this case, the effect ofGL183 mAb (inhibition) was opposite that
ofPHA or of stimulatory anti-CD2 or anti-CD16 mAbs, which consistently enhanced
the target cell lysis. When added in combination with one or another of the stimuli
above, GL183 mAb sharply inhibited their enhancing effects. These data suggest
that GL183 surface molecules may also exert a regulatory role on the human NK
cell activation.
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